Case ReportLymphoma and Immunosuppression: A Report of a Case Associated With Efalizumab Therapy
Introduction
Well-established risk factors for lymphoma include uncommon immunodeficiency disorders such as hypogammaglobulinemia, HIV/AIDS, and organ transplantation. B-cell lymphomagenesis may be attributed to local T-cell–dependent antigen-driven proliferation of B cells that eventually become monoclonal and develop into lymphoma. Resistance to apoptosis may be acquired in autoimmune disorders and may be mediated by BCL2 expression, activation of nuclear factor–κB by inflammatory cytokines and growth factors as well as abnormalities in the expression of B-cell activating factor.1
Autoimmune disorders such as rheumatoid arthritis, systemic lupus, and Sjogren syndrome have been shown to have an increased risk of lymphoproliferative disorders.1, 2 An increased risk of cutaneous T-cell lymphomas and Hodgkin lymphoma has also been described with psoriasis.3 In addition to any increased risk of malignancy conferred by individual rheumatic diseases, there is also a potential risk related to the duration of exposure to immunosuppressive drugs such as azathioprine, methotrexate, cyclophosphamide, and chlorambucil.4, 5, 6, 7, 8, 9 Biologic response modifiers such as infliximab and adalimumab have also been associated with a possible risk of the development of lymphoproliferative disease.10 We describe a case of a patient with psoriasis who developed lymphoma while receiving the biologic drug efalizumab that spontaneously regressed on withdrawal of the immunosuppressive agent.
Section snippets
Case Report
A 55-year-old black male on weekly efalizumab therapy for 2 years to treat generalized psoriasis presented with a 4-week history of fatigue, back pain, and weight loss of 11 kg. There was no history of fever, night sweats, headache, or seizures. His past medical history was significant for diabetes mellitus, hypertension, autoimmune hypothyroidism, and psoriasis. Concomitant medications included metoprolol, hydrochlorothiazide, levothyroxine, metformin, and pioglitazone.
His physical examination
Discussion
Efalizumab is a humanized monoclonal antibody that binds to the CD11a subunit of lymphocyte function–associated antigen 1 (LFA-1) on memory T cells, preventing LFA-1 binding to its ligand intercellular adhesion molecule 1 (ICAM-1) on vascular endothelial cells and keratinocytes. It rapidly reduces available CD11a binding sites and expression of CD11a on the surface of T lymphocytes. Downregulation of cell surface molecules such as VLA-4, 7 integrin, and L selectin limits the ability of T cells
Conclusion
Biologic agents are an efficacious way to treat various chronic inflammatory states but are also associated with the development of lymphoproliferative disorders. They should be used with caution and prudence in an already immunosuppressed patient population. Vigilance and a high index of suspicion are warranted in the care and continued follow-up of patients on long-term treatment with these medications. Further studies looking into these agents' oncologic potential should be encouraged.
Disclosures
Alan Menter is on the advisory board and serves as a consultant, investigator and speaker for Abbott Laboratories, Amgen, Astellas Pharma Inc., Centocor, Inc., Genentech, Inc., Warner Chilcott, and Wyeth Pharmaceuticals. He is on the advisory board, serves as a consultant, and has been on a Speaker's Bureau for Galderma, is an investigator for Allergan, Asubio Pharmaceuticals, Inc., Celgene Corporation, DUSA Pharmaceuticals, Inc., Eli Lilly and Company, Novartis Pharmaceuticals Corporation,
References (31)
- et al.
The risk of lymphoma in patients with psoriasis
J Invest Dermatol
(2006) - et al.
Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France
Blood
(2002) - et al.
Immunobiologics in the treatment of psoriasis
Clin Immunol
(2007) - et al.
Blockade of CD1 1a by efalizumab in psoriasis patients induces a unique state of T-cell hyporesponsiveness
J Invest Dermatol
(2008) - et al.
Atypical CD8+ cutaneous T-cell lymphoma after immunomodulatory therapy
Clin Lymphoma Myeloma
(2006) - et al.
Cancer risk in a population based cohort of patients hospitalized for psoriasis in Sweden
J Invest Dermatol
(2001) The management of lymphoma in the immunosuppressed patient
Best Pract Res Clin Haematol
(2002)- et al.
Malignant lymphomas in autoimmunity and inflammation: a review of risks, risk factors, and lymphoma characteristics
Cancer Epidemiol Biomarkers Prev
(2006) - et al.
Prior medical conditions and medication use and risk of non-Hodgkin lymphoma in Connecticut United States women
Cancer Causes Control
(2004) - et al.
Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases
J Rheumatol
(1999)
Does exposure to immunosuppressive therapy increase the 10 year malignancy and mortality risks in rheumatoid arthritis? A matched cohort study
Br J Rheumatol
Hodgkin's lymphoma in a patient of psoriasis treated with long-term, low-dose methotrexate therapy
Indian J Dermatol Venereol Leprol
Two cases of methotrexate induced lymphomas in rheumatoid arthritis: an association with increased serum IgE
J Rheumatol
Non-Hodgkin's lymphoma in patients with rheumatoid arthritis treated with low dose methotrexate
J Rheumatol
Complications and adverse reactions in the use of newer biologic agents
Semin Cutan Med Surg
Cited by (0)
This summary may include the discussion of investigational and/or unlabeled uses of drugs and/or devices that may not be approved by the FDA.
Electronic forwarding or copying is a violation of US and International Copyright Laws.
Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by CIG Media Group, LP, ISSN #2152-2650, provided the appropriate fee is paid directly to Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923 USA. www.copyright.com 978-750-8400.